6th Edition of Euro-Global Conference on Biotechnology and Bioengineering
September 28-30 | Hybrid Event
CRISPR & Genome Editing Technologies
The advent of CRISPR & genome editing technologies has ushered in a new era of genetic precision, enabling targeted modifications with unprecedented accuracy. CRISPR-Cas systems allow scientists to cut, delete, or replace DNA sequences in a wide range of organisms, offering therapeutic possibilities for genetic diseases, cancer, and infectious conditions. Beyond CRISPR, novel editing tools like base editors and prime editors are expanding the genome editing toolkit. Researchers are now combining CRISPR & Genome Editing Technologies with delivery platforms such as viral vectors and nanoparticles to improve efficiency and specificity. These tools are also critical for functional genomics, crop enhancement, and synthetic biology. As ethical and regulatory frameworks evolve, genome editing remains one of the most transformative technologies in modern biotechnology.
Murray Moo Young
University of Waterloo, Canada
Limongi Tania
University of Turin, Italy
Luis Jesus Villarreal Gomez
Universidad Autonoma de Baja California, MexicoSubmit your abstract Today
Title : Renewed novel biotech ideas, with bioreactor bioengineering economic impact
Murray Moo Young, University of Waterloo, Canada
Title : Improving health in over 40,000 patients: The impact of nanomedicine fighting antibiotic resistant infections
Thomas J Webster, Brown University, United States
Title : Osmotic lysis–driven Extracellular Vesicle (EV) engineering
Limongi Tania, University of Turin, Italy
Title : Evaluating cell compatibility and subcutaneous host response of silk fibroin–chitosan plug composites as potential resorbable implants
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Comparative study of endo-?-1,4-mannanases from novel bacterial strains for the production of galactomanno-oligosaccharides
Shruti Saini, National Agri-food and Bio-manufacturing Institute, India
Title : Engineering Sf9 host cells with AcMNPV genes to control baculovirus infection dynamics and heterologous gene expression
Tamer Z Salem, Zewail City of Science and Technology, Egypt